Trademark
Full logoAbout Incyte Corporation
Incyte Corporation is a biopharmaceutical company anchored by Jakafi (ruxolitinib) — its flagship JAK inhibitor used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, plus the topical Opzelura formulation for atopic dermatitis and vitiligo. Headquartered in Wilmington, Delaware, the company has built a deep oncology pipeline anchored by JAK and other kinase inhibitors. Incyte also collaborates with multiple partners on out-licensed assets that have generated meaningful royalty streams.
About the Incyte Corporation logo
The Incyte Corporation (INCY) logo is part of the Tickericons pack — a hand-crafted set of logos for every company in the S&P 500. Each logo is manually redrawn to a consistent grid, weight, and corner radius so INCY sits cleanly next to other tickers in cap tables, dashboards, equity research, and fintech UI.
You get two styles: the trademark (just the symbol, ideal for grids and tight UI) and the full logo (mark plus wordmark, ideal when there's room to breathe). Both ship as scalable SVG, high-resolution PNG, and reusable Figma components.
Is Incyte Corporation in the S&P 500?
Yes. Incyte Corporation (INCY) is a member of the S&P 500 and has been since Feb 28, 2017. It is classified under the Health Care sector. See every S&P 500 addition and removal.
Index history
Feb 28, 2017 · Added to the S&P 500
SE acquired by ENB
Other Health Care companies
See all →
abtAbbott LaboratoriesMar 4, 195725,460
abbvAbbVieDec 31, 20125,069
aAgilent TechnologiesJun 5, 20009,661
algnAlign TechnologyJun 19, 20173,438
amgnAmgenJan 2, 199212,738
baxBaxter InternationalSep 30, 197219,771
bdxBecton Dickinson and CoSep 30, 197219,771
techBio-Techne CorporationAug 30, 20211,905
biibBiogenNov 13, 20038,405
bsxBoston Scientific CorporationFeb 24, 199511,589
Get all S&P 500 logos
One-time payment. SVG, PNG, and a Figma library. Free updates as the index changes.


